The Mechanics of Drug Pricing: How the FTC's Settlement with CVS Caremark Reshapes PBM Rebates and Deductibles

The Federal Trade Commission has finalized a sweeping settlement with CVS Caremark, fundamentally restructuring how one of the nation's largest pharmacy benefit managers (PBMs) prices prescription drugs. Announced on July 14, 2026, the agreement resolves a high-stakes antitrust lawsuit and mandates a shift away from the opaque rebate models that have defined the pharmaceutical supply chain for decades.[1][2]

The core of the FTC's 2024 lawsuit centered on insulin, alleging that the "Big Three" PBMs—CVS Caremark, Express Scripts, and OptumRx—artificially inflated list prices by favoring medications that offered the largest manufacturer rebates. Because these three entities control roughly 80% of all U.S. prescriptions, their formulary decisions dictate which drugs are accessible and affordable for the vast majority of insured Americans.[1][3]

To understand the mechanics of the settlement, one must first understand the "rebate wall." Historically, drug manufacturers set a high "list price" for a medication. They then negotiate with PBMs, offering steep, confidential rebates to ensure their drug is placed on a preferred tier of the health plan's formulary.[3][6]

Under the traditional model, the PBM and the health plan sponsor (the employer) kept a significant portion of these rebates. However, the patient's deductible and coinsurance were calculated based on the artificially high list price, not the discounted net price. This dynamic effectively forced sick patients to subsidize the premiums of healthy employees, while PBMs profited from the spread.[6][7]

The new settlement dismantles this architecture through a mechanism called "delinking." CVS Caremark is now prohibited from tying its administrative fees or compensation to a drug's list price. By severing this link, the PBM no longer has a financial incentive to favor a $300 drug with a $200 rebate over a drug that simply costs $100 upfront.[2][3]

The most immediate impact for consumers will arrive via "point-of-sale rebates." The agreement requires CVS Caremark to align a member's cost-sharing directly with the net cost of the medication after rebates are applied. When a patient walks up to the pharmacy counter, their deductible or coinsurance will be calculated based on the actual negotiated price, pushing the savings directly to the consumer.[2][4]

The financial implications of this mechanical shift are massive. FTC Chairman Andrew N. Ferguson, who served as the sole voting member to approve the deal following a recusal, estimates the settlement will lock in $8.5 billion in broad consumer savings over the next decade. An additional $4.5 billion in savings is expected specifically from the implementation of point-of-sale rebates.[1][3]

CVS Caremark has positioned the settlement not as a punitive correction, but as an acceleration of its existing strategy. Ed DeVaney, President of CVS Caremark, stated that the agreement "advances and reinforces the changes we have already put in place." The company noted that it negotiated nearly $80 billion in savings for clients last year and had already begun offering point-of-sale rebate options that saved patients $900 million.[4]

Beyond rebates, the settlement targets a controversial practice known as "spread pricing." In a spread pricing model, a PBM charges a health plan sponsor (like an employer) $100 for a prescription, but only reimburses the dispensing pharmacy $70, pocketing the $30 difference. CVS Caremark has agreed to simplify its pricing structures and move its standard commercial offerings away from spread pricing entirely.[4][6]

This shift offers a critical lifeline to independent and community pharmacies, which have long argued that PBM reimbursement rates are unpredictable and often fail to cover the actual cost of acquiring the drugs. Under the settlement, CVS Caremark will allow retail community pharmacies the opportunity to shift to a transparent "cost-plus" reimbursement model.[1][6]

The agreement also includes provisions that protect pharmacies from retaliation. The FTC mandate prevents Caremark from unfairly interfering with pharmacies' ability to work with independent hub service providers, ensuring that smaller pharmacies can utilize third-party administrative tools without fear of being dropped from the PBM's network.[1][2]

In a nod to the evolving federal healthcare landscape, the settlement mandates integration with new government discount platforms. Once supporting regulations are finalized, CVS Caremark must count eligible prescription purchases made through the White House's "TrumpRx" platform toward a patient's health plan deductibles and out-of-pocket maximums.[5]

This requirement closes a significant loophole. Previously, if a patient found a cheaper cash price for a drug on a direct-to-consumer discount platform, paying cash meant the money did not count toward their insurance deductible, leaving them exposed to higher costs later in the year.[5]

The CVS Caremark settlement is the second major domino to fall in the FTC's campaign. Express Scripts reached a highly similar settlement with the agency in February 2026, which also mandated delinking and point-of-sale rebates. UnitedHealth Group's OptumRx remains the last of the "Big Three" without a finalized agreement, though industry analysts expect a resolution shortly.[1][7]

For employers and plan sponsors, the settlement introduces new fiduciary responsibilities. Because the agreement expands transparency—requiring enhanced reporting on drug pricing, rebates, and broker compensation—employers now have the data necessary to rigorously audit their PBM contracts. Under the Employee Retirement Income Security Act (ERISA), plan sponsors must ensure these newly transparent savings are actually benefiting their employees.[4][6]

While the settlement mandates these transparent, pass-through models as the "standard offering" for commercial clients, employers still have to actively select and enforce them. The ultimate success of the FTC's intervention will depend on whether corporate HR departments transition their health plans to these new cost-plus frameworks, or if the inertia of legacy contracts slows the rollout of consumer savings.[1][4]